Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (KESTREL)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02551159 |
Recruitment Status :
Completed
First Posted : September 16, 2015
Results First Posted : October 13, 2021
Last Update Posted : October 13, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Squamous Cell Carcinoma of the Head and Neck | Biological: MEDI4736 Biological: Tremelimumab Biological: MEDI4736+Tremelimumab Biological: Cetuximab Drug: 5-fluorouracil (5FU) Drug: Cisplatin Drug: Carboplatin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 823 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients |
Actual Study Start Date : | October 15, 2015 |
Actual Primary Completion Date : | July 6, 2020 |
Actual Study Completion Date : | May 21, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Monotherapy
MEDI4736 monotherapy.
|
Biological: MEDI4736
Anti-PD-L1 antibody |
Experimental: Combination Therapy
MEDI4736+Tremelimumab combination therapy
|
Biological: Tremelimumab
Anti-CTLA-4 Antibody Biological: MEDI4736+Tremelimumab |
Active Comparator: Standard of Care
Standard of Care treatment
|
Biological: Cetuximab
Monoclonal Antibody Drug: 5-fluorouracil (5FU) Chemotherapy Agent Drug: Cisplatin Chemotherapy agent Drug: Carboplatin Chemotherapy Agent |
- Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC) [ Time Frame: From date of randomization until time of final analysis, an average of approximately 4 years ]Number of participants with Overall Survival (OS)
- Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup [ Time Frame: From date of randomization until time of final analysis, an average of approximately 4 years ]Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)
- Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC) [ Time Frame: From date of randomization until time of final analysis, an average of approximately 4 years ]Number of participants with Overall Survival (OS)
- Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup [ Time Frame: 12, 18 and 24 months after randomization ]Percentage of patients alive
- Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup [ Time Frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years ]Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
- Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup [ Time Frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years ]Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: >= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)
- Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup [ Time Frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years ]Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
- Overall Survival (OS) Status in the All-comers (Full Analysis Set) [ Time Frame: From date of randomization until time of final analysis, an average of approximately 4 years ]Number of participants with Overall Survival (OS)
- Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set) [ Time Frame: From date of randomization until time of final analysis, an average of approximately 4 years ]Time from the date of randomization until death due to any cause (i.e., date of death or censoring - date of randomization + 1)
- Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set) [ Time Frame: 12, 18 and 24 months after randomization ]Percentage of patients alive
- Progression Free Survival (PFS) in the All-comers (Full Analysis Set) [ Time Frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years ]
Time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression).
Progression is defined using Response Evaluation Criteria in Solid Tumours criteria (RECIST v1.1), as ≥20% increase in the sum of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
- Objective Response Rate (ORR) in the All-comers (Full Analysis Set) [ Time Frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years ]Number (%) of patients with at least 1 visit response of complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) for target lesions (TL) and assessed by MRI or CT: CR: Disappearance of all TLs since baseline; PR: >= 30% decrease in the sum of diameters of TLs; Overall Response (OR = CR + PR)
- Duration of Response (DoR) in the All-comers (Full Analysis Set) [ Time Frame: Tumor assessments (per RECIST 1.1) every 6 weeks for the first 24 weeks relative to the date of randomization and then every 8 weeks thereafter, up to approximately 4 years ]Time from the date of first documented response until the first date of documented progression or death in the absence of disease progression
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 130 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥18 years at the time of screening
- Documented evidence of recurrent or metastatic SCCHN (oral cavity, oropharynx, hypopharynx, or larynx).
- A fresh tumor biopsy for the purpose of screening or an available archival tumor sample. Tumor lesions used for fresh biopsies should not be the same lesions used as RECIST target lesions, unless there are no other lesions suitable for biopsy.
- No prior systemic chemotherapy for recurrent or metastatic disease
- World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
- No prior exposure to immune-mediated therapy,
Exclusion Criteria:
- Histologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)
- Tumor progression or recurrence within 6 months of last dose of platinum therapy in the primary treatment setting
- Receipt of any radiotherapy or hormonal therapy for cancer treatment within 30 days prior to first dose of study treatment
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02551159
Study Director: | Richard Olsson | ||
Principal Investigator: | Tanguy Seiwert | The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637 |
Documents provided by AstraZeneca:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT02551159 |
Other Study ID Numbers: |
D419LC00001 |
First Posted: | September 16, 2015 Key Record Dates |
Results First Posted: | October 13, 2021 |
Last Update Posted: | October 13, 2021 |
Last Verified: | September 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
Access Criteria: | When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen 4 {CTLA-4}, PFS, SCCHN |
Head and Neck Neoplasms Squamous Cell Carcinoma of Head and Neck Carcinoma, Squamous Cell Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms by Site Carboplatin Fluorouracil Cetuximab |
Durvalumab Tremelimumab Antibodies, Monoclonal Antineoplastic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Immunological |